Drug Profile
Research programme: Parkinson's disease therapeutics - Imago Pharmaceuticals/MJFF
Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Imago Pharmaceuticals
- Developer The Michael J. Fox Foundation for Parkinson's Research
- Class Antiparkinsonians
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors; Parkin protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 11 May 2015 Preclinical trials in Parkinson's disease in USA (unspecified route)